Eli Lilly plans to buy privately held Merida Biosciences for up to $2.88 billion in cash, according to a report from CNBC published on August 31, 2026. The deal, if completed, would add Merida's portfolio to Lilly's pipeline, though the specific assets or therapeutic areas involved were not disclosed in the report.
The acquisition comes as large pharmaceutical companies continue to seek external innovation to bolster their drug development efforts. The all-cash consideration of up to $2.88 billion suggests a significant valuation for the private biotech, but the exact structure of the payments—whether upfront or milestone-based—was not detailed.
A cash deal for a private biotech
CNBC reported the planned acquisition on its top news feed, citing the deal value as "up to $2.88 billion in cash." The report did not specify the timing of the transaction or any regulatory approvals required. Merida Biosciences, as a privately held company, has not publicly disclosed its financials or pipeline, leaving the strategic rationale for the acquisition largely under wraps.
What the acquisition means for Lilly
For Eli Lilly, the move fits a pattern of acquiring external assets to complement its internal research. The company has not yet issued an official statement beyond the CNBC report, so investors will be watching for confirmation and further details. The deal's size, relative to Lilly's market capitalization, is modest, but the cash consideration underscores the company's financial capacity to pursue such transactions.
Open questions remain
The announcement raises several questions: What does Merida Biosciences bring to Lilly? When is the deal expected to close? And will regulators scrutinize the acquisition? As of now, neither Eli Lilly nor Merida Biosciences has publicly commented beyond the CNBC report, leaving these details for future announcements.